ALX Oncology Holdings Inc.
ALXO
$0.5214
-$0.0203-3.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.50% | -18.82% | -5.80% | -18.75% | -11.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.25% | -38.87% | 12.91% | 17.26% | 49.05% |
| Operating Income | 36.25% | 38.87% | -12.91% | -17.26% | -49.05% |
| Income Before Tax | 35.87% | 39.78% | -15.34% | -17.88% | -48.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 35.87% | 39.78% | -15.34% | -17.88% | -48.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.87% | 39.78% | -15.34% | -17.88% | -48.07% |
| EBIT | 36.25% | 38.87% | -12.91% | -17.26% | -49.05% |
| EBITDA | 36.43% | 39.04% | -12.42% | -17.37% | -48.89% |
| EPS Basic | 40.49% | 52.98% | 9.05% | 3.90% | -23.17% |
| Normalized Basic EPS | 40.48% | 52.98% | 9.04% | 3.90% | -23.40% |
| EPS Diluted | 40.49% | 52.98% | 9.05% | 3.90% | -23.17% |
| Normalized Diluted EPS | 40.48% | 52.98% | 9.04% | 3.90% | -23.40% |
| Average Basic Shares Outstanding | 7.77% | 28.06% | 26.80% | 22.66% | 20.22% |
| Average Diluted Shares Outstanding | 7.77% | 28.06% | 26.80% | 22.66% | 20.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |